-+ 0.00%
-+ 0.00%
-+ 0.00%
SOPHiA GENETICS Q3 2026 net loss widens to USD 20.27 million; Q3 2026 revenue rises 25% to USD 24.27 million
Share
Listen to the news
SOPHiA GENETICS Q3 2026 net loss widens to USD 20.27 million; Q3 2026 revenue rises 25% to USD 24.27 million
  • SOPHiA GENETICS’ third-quarter 2026 net loss widened to USD 20.27 million.
  • Revenue rose 25% year-over-year to USD 24.27 million.
  • The company signed 30 new core genomics customers and closed three material BioPharma deals.
  • Full-year 2026 revenue is expected at the upper end of the previously issued USD 94 million–USD 96 million guidance range.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030645PR_NEWS_USPR_____NE87113) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending